Vanguard Personalized Indexing Management
KRYS icon

Vanguard Personalized Indexing Management’s Krystal Biotech KRYS Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Buy
3,309
+282
+9% +$84.3K 0.01% 884
2026
Q1 		$782K Buy
3,027
+900
+42% +$239K 0.01% 1053
2025
Q4 		$524K Buy
2,127
+116
+6% +$24.4K 0.01% 1231
2025
Q3 		$355K Buy
2,011
+316
+19% +$47.3K ﹤0.01% 1411
2025
Q2 		$233K Sell
1,695
-251
-13% -$36.9K ﹤0.01% 1555
2025
Q1 		$351K Buy
1,946
+546
+39% +$91.8K 0.01% 1272
2024
Q4 		$219K Sell
1,400
-138
-9% -$24.5K ﹤0.01% 1486
2024
Q3 		$280K Buy
1,538
+164
+12% +$31.6K ﹤0.01% 1375
2024
Q2 		$252K Buy
+1,374
New +$231K ﹤0.01% 1345

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Personalized Indexing Management's KRYS Position: Q2 2026 in Review

Vanguard Personalized Indexing Management increased its Krystal Biotech (KRYS) stake by 9.3% in Q2 2026, buying an estimated $84.3K and bringing the position to 3,309 shares worth $1.23M. The position accounts for 0.01% of the portfolio, ranked #884.

Vanguard Personalized Indexing Management first reported a position in KRYS in Q2 2024 and has held it in 9 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Vanguard Personalized Indexing Management held 3,309 shares of Krystal Biotech worth $1.23M as of Q2 2026.
  • Vanguard Personalized Indexing Management bought 282 Krystal Biotech shares in Q2 2026, an estimated $84.3K.
  • Krystal Biotech made up 0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #884 holding.
  • Vanguard Personalized Indexing Management first reported a position in Krystal Biotech in Q2 2024 and has held it in 9 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.